Clinical predictors associated with warfarin sensitivity

American Journal of Therapeutics

Volumn 23, Issue 6, 2016, Pages e1690-e1694

  Saleh, Mohammad I ^a  

^a UNIVERSITY OF JORDAN   (Jordan)

Author keywords

Bleeding risk; Over anticoagulation; Pharmacogenomics and clinical predictors; Warfarin sensitivity

Indexed keywords

AMIODARONE; CYTOCHROME P450 2C9; VITAMIN K EPOXIDE REDUCTASE; VKORC1 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGE; AGED; BODY HEIGHT; BODY WEIGHT; CHILD; DIABETES MELLITUS; DRUG RESISTANCE; FEMALE; GENETICS; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; METABOLISM, INBORN ERRORS; MIDDLE AGED; STATISTICAL MODEL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AMIODARONE; BODY HEIGHT; BODY WEIGHT; CHILD; CYTOCHROME P-450 CYP2C9; DIABETES MELLITUS; DRUG RESISTANCE; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; LOGISTIC MODELS; MALE; METABOLISM, INBORN ERRORS; MIDDLE AGED; VITAMIN K EPOXIDE REDUCTASES; YOUNG ADULT;

EID: 84995751285     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0000000000000248     Document Type: Article

References (32)

1. Cini M, Legnani C, Cosmi B, et al. A new warfarin dosing algorithm including VKORC1 3730 G . A polymorphism: comparison with results obtained by other published algorithms. Eur J Clin Pharmacol. 2012;68: 1167-1174.
2. Tan GM, Wu E, Lam YY, et al. Role of warfarin pharmacogenetic testing in clinical practice. Pharmacogenomics. 2010;11:439-448.
3. Lazo-Langner A, Kovacs MJ. Predicting warfarin dose. Curr Opin Pulm Med. 2010;16:426-431.
4. Budnitz DS, Lovegrove MC, Shehab N, et al. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365:2002-2012.
5. van der Meer FJ, Rosendaal FR, Vandenbroucke JP, et al. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med. 1993;153: 1557-1562.
6. Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med. 1995;333:11-17.
7. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inceptioncohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet. 1996;348:423-428.
8. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005;106: 2329-2333.
9. Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007;116:2563-2570.
10. Carlquist JF, Horne BD, Muhlestein JB, et al. Genotypes of the cytochrome p450 isoform, CYP2C9, and the Vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J Thromb Thrombolysis. 2006;22:191-197.
11. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360:753-764.
12. Saleh MI, Alzubiedi S. Dosage individualization of warfarin using artificial neural networks. Mol Diagn Ther. 2014;18:371-379.
13. Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood. 2000;96:1816-1819.
14. Gurwitz JH, Avorn J, Ross-Degnan D, et al. Aging and the anticoagulant response to warfarin therapy. Ann Intern Med. 1992;116:901-904.
15. Mungall D, White R. Aging and warfarin therapy. Ann Intern Med. 1992;117:878-879.
16. Kirking DM, Cohen IA, Shue ME, et al. Relationship of age, weight and body surface area to warfarin maintenance dose requirements. J Clin Hosp Pharm. 1985;10: 101-105.
17. Moreau C, Bajolle F, Siguret V, et al. Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. Blood. 2012;119:861-867.
18. Kamali F, Khan TI, King BP, et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther. 2004;75:204-212.
19. Heimark LD, Wienkers L, Kunze K, et al. The mechanism of the interaction between amiodarone and warfarin in humans. Clin Pharmacol Ther. 1992;51:398-407.
20. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther. 1997;73:67-74.
21. Wallin R, Wajih N, Hutson SM. VKORC1: a warfarinsensitive enzyme in Vitamin K metabolism and biosynthesis of Vitamin K-dependent blood coagulation factors. Vitam Horm. 2008;78:227-246.
22. Wang ZQ, Zhang R, Zhang PP, et al. Pharmacogeneticsbased warfarin dosing algorithm decreases time to stable anticoagulation and the risk of major haemorrage: an updated meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol. 2014. doi: 10.1097/FJC. 0000000000000204
23. Whirl-Carrillo M, McDonagh EM, Hebert JM, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92:414-417.
24. McDonagh EM, Whirl-Carrillo M, Garten Y, et al. From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. Biomark Med. 2011;5:795-806.
25. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352:2285-2293.
26. Lurie Y, Loebstein R, Kurnik D, et al. Warfarin and Vitamin K intake in the era of pharmacogenetics. Br J Clin Pharmacol. 2010;70:164-170.
27. Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001;119(Suppl 1): 8S-21S.
28. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165:1095-1106.
29. Chen LY, Eriksson N, Gwilliam R, et al. Gamma-glutamyl carboxylase (GGCX) microsatellite and warfarin dosing. Blood. 2005;106:3673-3674.
30. Shikata E, Ieiri I, Ishiguro S, et al. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood. 2004;103:2630-2635.
31. Kimmel SE, Christie J, Kealey C, et al. Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans. Pharmacogenomics J. 2008;8: 53-60.
32. Perera MA, Cavallari LH, Limdi NA, et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet. 2013;382:790-796.